NovaGo Therapeutics AG announces start of the Phase Ib SPROUT clinical trial
16-01-2025 – Our alumni project, CeNeReg (now NovaGo Therapeutics AG) has kickstarted the Phase Ib SPROUT clinical trial. The first patient has now been dosed with the NG004 drug to evaluate the safety and medicinal chemistry the antibody therapy on patients with acute spinal cord injury.
“This milestone marks Novago’s transition to a clinical stage company with its first asset. We are thrilled to start the clinical development of NG004 for acute spinal cord injury.” said Stefan Moese, CEO of Novago.
“Seeing NG004 transition to clinical trials is a significant achievement offering a much-needed, first-in-class treatment for patients with acute spinal cord injury.” Martin Schwab, CSO of Novago.
